Abacavir (Ziagen)

The Latest

Abacavir, Platelets, and a Cardiovascular Verdict: A Top HIV Clinical Development of 2018

Debates about the role of abacavir (Ziagen, ABC) in the development of cardiovascular disease in persons living with HIV have raged for over a decade, and a kind of stalemate has been achieved between those who are and are not convinced of a link. Wh...

By David Alain Wohl, M.D.

Reducing Risk of Myocardial Infarction in HIV-Positive People

This year at CROI 2018 a few studies tried to explore possible mechanisms for the association of increased myocardial infarction risk and abacavir use.

By Satyajit Das for HIV i-Base

Unexpected Side Effects With Generic Abacavir -- and Potential for Rare Reactions to Other Generic ARVs

Several anecdotal reports of mouth ulcers have recently been reported in people switching to generic abacavir in the UK.

By Simon Collins for HIV i-Base

What 2014 Development Has the Biggest Impact on HIV Care?

Each year we see new developments in HIV that improve the lives of those living with the disease and make it easier for providers to care for patients. We asked some of the leading experts what development this year they thought would have the biggest …

By Theo Smart and Myles Helfand

What's Hot in HIV Treatment

Here’s a recap of the biggest developments in HIV treatment over the past year, as well as a look at what’s to come.

By Warren Tong

Abacavir Link to Cardiovascular Events in High-Risk Patients Maintained in D:A:D Study

A poster at CROI 2014, presented by Caroline Sabin from University College London and colleagues, presented follow-up results from D:A:D since the initial findings in 2008 of a link between abacavir use and risk of myocardial infarction (MI) in peopl...

By Simon Collins for HIV i-Base

Approval of Generic Abacavir Tablets, 300 mg

On June 18, 2012, FDA granted approval for a generic formulation of abacavir tablets, 300 mg, manufactured by Mylan Pharmaceuticals, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

FDA has determined t...

By U.S. Food and Drug Administration

FDA Report Suggests Abacavir May Not Increase Myocardial Infarction Risk After All

In a poster that was presented on March 2 at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011), the U.S. Food and Drug Administration (FDA) reported that it has found no evidence of an association between abacavir (ABC, Zia...

By Nelson Vergel, B.S.Ch.E., M.B.A.

FDA Finds No Heart Attack Risk With HIV Drug

Food and Drug Administration officials said Tuesday that a data review of the AIDS drug abacavir revealed no greater risk of heart attacks than other HIV medicines. Doctors should continue to prescribe abacavir as directed, the agency said. FDA's ana...

By CDC National Prevention Information Network

FDA Study Finds No Link Between Ziagen and Heart Attacks

A US Food and Drug Administration (FDA) analysis of 26 trials comparing Ziagen (abacavir) to other drugs found no evidence that this antiretroviral raises the risk of myocardial infarction (heart attack).1 Ziagen is part of the two-drug combination E...

By The Center for AIDS Information & Advocacy